Trial details
Immune response dynamics in Gleason 9-10 patients undergoing radiotherapy: A proof of principle study
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: ICIC
Official title: Immune response dynamics in Gleason 9-10 patients undergoing radiotherapy: A proof of principle study
Principal Investigator:
Cancer type: Genitourinary
Cancer location: Prostate
Disease stage: Advanced Cancer
Trial phase: Other
Intervention: Radiation Therapy: External beam radiotherapy, androgen deprivation therapies and brachytherapy
Registration #: N/A
Trial description:
The purpose of this study is to look at the body’s response to radiation treatment with or without brachytherapy (BT) in patients with prostate cancer. Patients who have high-grade prostate cancers (Gleason 9-10) who meet a certain criteria may be able to participate. There will be two groups of patients participating in this study; one group will receive External beam radiotherapy (EBRT) and androgen deprivation therapies (ADT); while the second group will receive EBRT+ADT and BT. The patient’s doctor will choose the group the patient is in and patients will know which treatment they are receiving.
Inclusion Criteria: • All individuals must be male and have a diagnosis of Gleason 9-10 prostate cancer • Gleason 9-10 prostate cancer suitable for radical treatment with radiotherapy • Signed consent form Exclusion Criteria: • Immune compromised patient • Did not sign consent form
